Salbutamol increases leg glucose uptake and metabolic rate but not muscle glycogen resynthesis in recovery from exercise

Research output: Contribution to journalJournal articlepeer-review

Content: Exercise blunts the effect of beta2-agonist on peripheral glucose uptake and energy expenditure. Whether such attenuation extends into recovery is unknown.

Objective: To examine the effect of beta2-agonist on leg glucose uptake and metabolic rate in recovery from exercise.

Design: Using leg arteriovenous balance technique and analyses of thigh muscle biopsies, we investigated the effect of beta2-agonist (24 mg oral salbutamol) vs placebo on leg glucose, lactate, and oxygen exchange before, during, and 0.5-5-h in recovery from quadriceps exercise, as well as on muscle glycogen resynthesis and activity in recovery. Twelve healthy, lean young men participated.

Results: Before exercise, leg glucose uptake was 0.42±0.12 and 0.20±0.02 mmol×min-1 (mean±SD) for salbutamol and placebo (= .06), respectively, while leg oxygen consumption was around two-fold higher (< .01) for salbutamol than for placebo (25±3 vs 14±1 mL×min-1). No treatment differences were observed in leg glucose uptake, lactate release, and oxygen consumption during exercise. But in recovery, cumulated leg glucose uptake, lactate release, and oxygen consumption was 21 mmol (95% CI: 18-24, = .018), 19 mmol (95%CI: 16-23, < .01), and 1.8 L (95% CI: 1.6-2.0, < .01) higher for salbutamol than for placebo, respectively. Muscle glycogen content was around 30% lower (< .01) for salbutamol than for placebo in recovery, whereas no treatment differences were observed in muscle glycogen resynthesis or glycogen synthase activity.

Conclusions: Exercise blunts the effect of beta2-agonist on leg glucose uptake, but this attenuation diminishes in recovery. Beta2-agonist increases leg lactate release in recovery, which may relate to glycolytic trafficking due to excessive myocellular glucose uptake.

Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume107
Issue number3
Pages (from-to)e1193-e1203
Number of pages11
ISSN0021-972X
DOIs
Publication statusPublished - 2022

Bibliographical note

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

    Research areas

  • Faculty of Science - Thermogenesis, Adrenoceptor, Glycogenolysis, cAMP, PKA, Beta-agonist, Clenbuterol

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 282531877